Literature DB >> 18849299

Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/interleukin-6 pathway.

Chia-Yu Chu1, Shih-Ting Cha, Wan-Chi Lin, Po-Hsuan Lu, Ching-Ting Tan, Cheng-Chi Chang, Ben-Ren Lin, Shiou-Hwa Jee, Min-Liang Kuo.   

Abstract

Stromal cell-derived factor 1alpha (SDF-1alpha) (CXCL12) has been observed to enhance tumor angiogenesis. However, the comprehensive role of SDF-1alpha (CXCL12)-CXCR4 interaction, exerted during angiogenesis, has not been well understood. We have previously demonstrated that human basal cell carcinoma (BCC) tissues and a BCC cell line (BCC-1/KMC) had significant expression of CXCR4, whose level was higher in invasive than in the non-invasive BCC types. Here, we observed that human BCC tissues with high expression levels of CXCR4 had higher vascularity. Further, among the 71 BCCs diagnosed between the years 2004-2005, BCCs with high CXCR4 expression had concomitantly higher microvessel density, as compared with those with low CXCR4 expression (P < 0.001). We found that SDF-1alpha induced angiogenic activity in human BCC cells, both in vitro and in vivo. SDF-1alpha significantly upregulated several angiogenesis-associated genes such as interferon-alpha-inducible protein 27, interleukin (IL)-6, bone morphogenetic protein (BMP)-6, SOCS2 and cyclooxygenase 2 (COX)-2 in human BCC cells. Among them, IL-6 was the earliest and highest upregulated gene whose induction was observed within 6 h of the commencement of SDF-1alpha-CXCR4 interaction. The mechanisms behind the SDF-1alpha-induced time and dose-dependent upregulation of messenger RNA expression and protein secretion of IL-6 were investigated. The transcriptional regulation of IL-6 by SDF-1alpha was mediated by phosphorylation of extracellular signal-related kinase 1/2 and activation of the nuclear factor-kappaB complex. The identification of the angiogenic profiles induced through SDF-1alpha-CXCR4 interactions in human BCC cells may contribute further insights into the mechanisms involved in the angiogenic potential of SDF-1alpha (CXCL12).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18849299     DOI: 10.1093/carcin/bgn228

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  20 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  CXCR4 in epidermal keratinocytes: crosstalk within the skin.

Authors:  Wendy B Bollag; William D Hill
Journal:  J Invest Dermatol       Date:  2013-11       Impact factor: 8.551

3.  Activation of CXCL12/CXCR4 renders colorectal cancer cells less sensitive to radiotherapy via up-regulating the expression of survivin.

Authors:  Dawei Wang; Chengbin Jiao; Yanli Zhu; Deshen Liang; Ming Zao; Xiangyu Meng; Jianwei Gao; Yunlong He; Weixin Liu; Jie Hou; Zhaohua Zhong; Zhuoxin Cheng
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-23

4.  TGFβ, Fibronectin and Integrin α5β1 Promote Invasion in Basal Cell Carcinoma.

Authors:  François Kuonen; Isabelle Surbeck; Kavita Y Sarin; Monique Dontenwill; Curzio Rüegg; Michel Gilliet; Anthony E Oro; Olivier Gaide
Journal:  J Invest Dermatol       Date:  2018-07-14       Impact factor: 8.551

Review 5.  The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy.

Authors:  Yong Lin; Lang Bai; Wenjie Chen; Shanling Xu
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

6.  G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway.

Authors:  Shih-Ting Cha; Ching-Ting Tan; Cheng-Chi Chang; Chia-Yu Chu; Wei-Jiunn Lee; Been-Zen Lin; Ming-Tsan Lin; Min-Liang Kuo
Journal:  Nat Cell Biol       Date:  2016-08-15       Impact factor: 28.824

7.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 8.  Structure-based drug design: from nucleic acid to membrane protein targets.

Authors:  Magdalena M Dailey; Chayanendu Hait; Patrick A Holt; Jon M Maguire; Jason B Meier; M Clarke Miller; Luigi Petraccone; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-31       Impact factor: 3.362

9.  Cell migration to CXCL12 requires simultaneous IKKα and IKKβ-dependent NF-κB signaling.

Authors:  Richard R Kew; Kenneth B Marcu; Marianna Penzo; David M Habiel; Mahalakshmi Ramadass
Journal:  Biochim Biophys Acta       Date:  2014-04-18

10.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Authors:  Lorenzo Anasagasti-Angulo; Yanelda Garcia-Vega; Silvia Barcelona-Perez; Pedro Lopez-Saura; Iraldo Bello-Rivero
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.